LDA, short for Low Dose Allergens or Ultra Low Dose Enzyme Activated Immunotherapy, is an innovative approach to immunotherapy that uses extremely small doses of beta glucuronidase and specific allergens to help regulate the immune system.
It is theorized that LDA works by encouraging the production of T-regulatory cells (T Reg cells), which help balance immune responses and reduce inappropriate reactions where the body mistakenly identifies harmless substances as threats.
Originally pioneered in the United States by W.A. Shrader, Jr., MD in 2002, LDA has been used as an option for individuals with a variety of allergy and sensitivity concerns.
LDA has been used for conditions such as hay fever, asthma, eczema, food allergies, and other immune-related sensitivities. It has also been safely used in young children, including infants as young as one month of age.
Pimri Pediatrics began offering LDA therapy in 2023 and has provided treatment to dozens of children, with a very high level of parent satisfaction. Contact us today to schedule an LDA consultation.
Conventional allergy immunotherapy, commonly known as “allergy shots,” works through a different immune pathway than Low Dose Allergen Therapy (LDA).
Traditional immunotherapy begins with allergen doses around 1 to 10,000 and gradually increases to much higher concentrations. The goal is to stimulate production of IgG “blocking antibodies,” which help prevent mast cells from releasing histamine — the chemical responsible for many allergy symptoms.
While effective for some patients, achieving these higher doses may cause significant reactions before improvement occurs. Possible reactions can include swelling, severe allergic responses, anaphylaxis, and other serious complications.
Traditional allergy shots are usually given multiple times per week during the initial phase and require ongoing maintenance treatments. Even after reaching maintenance doses, stopping treatment may result in symptoms returning within months for many patients.
LDA focuses on supporting immune regulation through ultra-low-dose therapy rather than progressively increasing allergen exposure. This approach offers another option for families exploring individualized allergy and sensitivity care.
The response rate for conditions treated with LDA varies depending on the condition being addressed. Many patients experience meaningful improvement when therapy is appropriately selected and combined with individualized care.
Like any therapy, LDA requires commitment and preparation. Most patients need to follow a very restricted diet beginning the day before treatment, continuing on the day of treatment, and for the day afterward.
Certain medications, including antihistamines and aspirin, may significantly reduce or interfere with the effectiveness of LDA if taken during the three weeks following treatment. Patients should discuss all medications and supplements with their healthcare provider before beginning therapy.
For families interested in learning more about the background, development, and history of LDA therapy, additional information is available through Dr. Shrader’s LDA resources.
Learn More About LDA Therapy